Ligamentum Teres Tenodesis in Developmental Dysplasia of the Hip

June 21, 2022 updated by: Ahmed Obeid Abd Allah, Al-Azhar University

The Role of Ligamentum Teres Tenodesis in the Management of Developmental Dysplasia of the Hip

The treatment of developmental dysplasia of the hip (DDH) remains challenging, yet recent advances have refined our understanding of how best to survey for the condition during infancy, minimize complications during early treatment, and refine the selection of patients who can best benefit from hip preservation surgery. The ideal continued target would be to prevent missed hip dislocations or dysplasia during the infant period, prevent avascular necrosis (AVN) during early treatment, and decrease the incidence of total hip arthroplasty in adulthood related to undertreated DDH, The goal of the treatment is to achieve a concentric reduction of the femoral head into the acetabulum.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

it is an operative technique to secure the femoral head after reduction in cases of developmental dysplasia of the hip

Operative technique:

The surgery will be accomplished under a general anesthesia.

An addition to the steps of the open reduction, the following were done:

  1. Identification of ligamentum teres
  2. ligamentum teres tenodesis

Study Type

Observational

Enrollment (Anticipated)

20

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

9 months to 5 years (Child)

Accepts Healthy Volunteers

N/A

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

The patients will be examined for:

  1. Length of both lower limbs in relation to each other.
  2. Length of both lower limbs according to patient age.
  3. Presence of hump related to the outer surface of the hip
  4. Presence of pain, abnormal gait, Trendlenburg test Radiographic evaluation (antero posterior and frog pelvis views)

An addition to the steps of the open reduction, the following were done:

  1. Identification of ligamentum teres
  2. ligamentum teres tenodesis

Description

Inclusion Criteria:

  • Patient with Developmental dysplasia of the hip (DDH) with :

    • Age: from 9 months -5 years old.
    • Virgin DDH.
    • Failed closed reduction in the management of DDH.
    • Failed open reduction through medial approach in the management of DDH

Exclusion Criteria:

  • • Paralytic hip dislocation .

    • Post septic hip dislocation.
    • Traumatic hip dislocation .
    • Age : below 9 months or above 5 years.
    • Refusal to participate in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Cohort
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
modified HHS
Time Frame: 6 months
score for function of the hip
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Al-Azhar University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

July 21, 2022

Primary Completion (Anticipated)

January 1, 2023

Study Completion (Anticipated)

February 1, 2023

Study Registration Dates

First Submitted

June 21, 2022

First Submitted That Met QC Criteria

June 21, 2022

First Posted (Actual)

June 27, 2022

Study Record Updates

Last Update Posted (Actual)

June 27, 2022

Last Update Submitted That Met QC Criteria

June 21, 2022

Last Verified

June 1, 2022

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • LTT

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Orthopedic Disorder

Clinical Trials on ligamentum teres tenodesis

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Armenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe